London – Popular Popular and Diabetes Diabetes of Novo Nordisk, Wegovy and Ozempic, can, in very rare cases, cause a serious eye condition that can lead to a loss of vision, the European Agency for the European Medicines Agency.
In the past, studies in type 2 diabetic patients have linked ozempic to the condition called anterior non -arteritic ischemic optical neuropathy. But it is the first time that a regulator has confirmed the side effect.
The condition can affect up to 1 in 10,000 people taking semaglutide, the active ingredient of Wegovy and Ozempic, as well as in the other drugs of NOVO Rybelsus diabetes, for at least a year, said the regulator.
The eye condition is the second most common cause of blindness due to lesions of the optic nerve, after glaucoma.
“This has been reported as a potential risk for some time, so I think the clinical community is relatively aware of it. I do not see it as making a major difference for prescription,” said Emily Field, Barclays analyst.
The actions listed by the United States of the Danish drug manufacturer increased almost 2.5% at the start of negotiations.
The security agency, which started its exam in December, asked Novo to add the eye condition as a side effect of a very rare frequency in information on products accompanying drugs that contain semaglutide.
Novo said it would work with the security agency to update labels, adding clinical trials and studies after the market did not suggest a reasonable possibility that drugs caused the condition.
The “risk profile of semaglutide services remains favorable,” the company said in a statement.
Novo recently faced investors’ concerns to lose its first engine advantage in the highly competitive market in the treatment of obesity, which led the company to oust CEO Lars Fruergaard Jorgensen in May.
Wegovy’s Zepbound and Eli Lilly is currently dominating the weight loss medication market, worth around 150 billion dollars over the next decade.
The European Medicines Agency Safety Committee has said that several major studies in type 2 diabetic patients have suggested that the use of Novo drugs could increase the risk of developing the eye condition by twice.
A study of nearly 350,000 patients with diabetes published in March has shown that the risk of developing the eye condition has more than doubled after two years of treatment with Ozempic, compared to patients taking drugs from other classes.
The United States Ministry of Health and Social Services did not immediately respond to a request for Reuters to comment whether the Food and Drug Administration conducts a side effect survey.
Contribution: Manas Mishra
The main dishes to remember from this article were generated with the help of large languages models and examined by our editorial team. The article, itself, is only written by man.
